Adaptive Biotechnologies(ADPT)

SEATTLE, WADiagnostics1 H-1B visas (FY2023)

Focus: Adaptive Biotechnologies is a Seattle-based diagnostics company leveraging T-cell sequencing technology to develop immune-based diagnostics across oncology, infectious disease, and inflammatory conditions. The company operates as a public mid-cap biotech with ~750 employees focused on precision diagnostics rather than traditional therapeutics.

Profile data last refreshed 7h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

501-1000

Open Jobs

15+13 this month

Growing — net +13 jobs in 30d

23 jobs added vs 10 removed. Steady team buildout.

Should You Work at Adaptive Biotechnologies?

AI assessment

Adaptive is an intriguing diagnostic innovator for professionals seeking immunology expertise and emerging-tech exposure, but financial headwinds and limited therapeutic pipeline present stability concerns for risk-averse candidates.

Why Work Here

Leader in T-cell receptor sequencing diagnostics with a differentiated platform (ClonoSEQ, T-Detect suite) addressing large markets in oncology and infectious disease

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

11 total

LOE Risk

Protected

No near-term cliffs

Hiring

Slowing

Jobs decreasing

Key Products

ClonoSEQ

Acute Lymphoblastic Leukemia (minimal residual disease detection)

Growth

Flagship T-cell sequencing diagnostic with 2 associated trials, representing core competency in oncology precision diagnostics.

T-Detect COVID

COVID-19 immune response detection

Help build intelligence for Adaptive Biotechnologies

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company with established revenue ($170M FY2025) and cash position ($48M) enabling stability and upward mobility for mid-career professionals

Strong R&D intensity (72%) signals investment in innovation and technical career development across diagnostics and immunology

Watch Out For

Declining revenue trajectory ($185M FY2024 → $170M FY2025) and persistent net losses (-$225M FY2025) indicate margin pressure and potential restructuring risk
Minimal pipeline depth with only 2 Phase 2 programs and no Phase 3 advancement; diagnostic-focused portfolio limits traditional pharma career progression for drug developers
Cash burn and declining cash position ($65M → $48M YoY) suggest limited runway for aggressive hiring or bonus cycles in near term

Generated by Claude from Adaptive Biotechnologies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Revenue

$170M

FY2025

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Early commercialized diagnostic with 3 trials; significant revenue driver during pandemic but declining as acute COVID market cools.

T-Detect Lyme

Lyme Disease detection

Early Growth

Emerging diagnostic targeting high-prevalence tick-borne illness with 1 clinical trial supporting development.

Pipeline & Clinical Trials

ImmuneSense

Inflammatory Bowel Diseases

N/A

Clinical Trials (4)

NCT04583982ImmuneSense™ COVID-19 Study

N/A

NCT05112874ImmuneSense™ COVID-19 Cross-Reactivity Study

N/A

NCT05769829ImmuneSense™ IBD Study

N/A

+1 more

ClonoSEQ

Acute Lymphoblastic Leukemia

N/A

Clinical Trials (2)

NCT04545333The clonoSEQ® Watch Registry

N/A

NCT05255354Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy

N/A

Autologous Stem Cell Transplant

Multiple Myeloma

N/A

Clinical Trials (1)

NCT05271630Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant

N/A

T-Detect COVID

COVID-19

N/A

ImmuneRACE

COVID-19

N/A

Clinical Trials (1)

NCT04494893ImmuneRACE - Immune Response Action to COVID-19 Events

N/A

T-Detect Lyme

Lyme Disease

N/A

mosunetuzumab

Diffuse Large B-Cell Lymphoma

Phase 2

Nivolumab

Bladder Cancer

Phase 2

bendamustine

Indolent Non-Hodgkin Lymphoma

Phase 2

Clinical Trials (1)

NCT06557330MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma

Phase 2

rituximab

Indolent Non-Hodgkin Lymphoma

Phase 2

venetoclax

Chronic Lymphocytic Leukemia

Phase 2

Clinical Trials (1)

NCT04419519Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

Phase 2

Interview Prep Quick Facts

Portfolio: 10 clinical trials

Top TAs: Oncology, Infectious Diseases, Immunology

H-1B (2023): 1 approval

SEC Filings: 2 available

Open Roles: 15 active jobs

Therapeutic Area Focus

Oncology

5 pipeline

Infectious Diseases

3 pipeline

Immunology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$170M8%

R&D Spend

$122M(72%)14%

Net Income

-$225M

Hiring Trend

Stable

Open Roles

Added

-1

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Adaptive Biotechnologies(ADPT)

Should You Work at Adaptive Biotechnologies?

Why Work Here

Key Products

Watch Out For

Pipeline & Clinical Trials

Open Jobs (15)

Account Operations Manager - Southeast

Strategic Alliance & Business Development Manager

Clinical Lab Technologist II

Commercial Counsel

Payer Contracting Manager

Accessioning Specialist II

Associate Director, Clinical Product Development

Vice President, Regulatory & Quality

Identity & Access Management Engineer II

Senior Payer Relations Specialist

Senior Machine Learning Scientist

Principal Machine Learning Scientist

Director / Senior Director, Sales & Business Development

Integration Engineer, EMR Connectivity

Diagnostics Hematology Specialist (North Central)

Financials (FY2025)

Hiring Trend

Visa Sponsorship